Literature DB >> 20153747

Effect of estrogen on electroretinographic responses in streptozotocin-induced diabetic female rats.

Haruhiro Yamashita1, Kazunari Sugihara, Chiaki Yamada, Shunsuke Tsutsumi, Yoshinobu Iwaki.   

Abstract

The aim of this study is to investigate the effects of estrogen on functional changes in the retinas of streptozotocin (STZ)-induced diabetic rats by using an electroretinography. Female rats were randomly divided into four treatment groups: (1) Control (sham operation and vehicle administration); (2) STZ (sham operation and STZ administration); (3) OVX (ovariectomy and vehicle administration); and (4) OVX + STZ (ovariectomy and STZ administration). Full-field electroretinograms (ERGs) were recorded before OVX and STZ administration and 4 and 12 weeks after STZ administration. At 4 weeks after STZ administration, although there were no differences in the STZ and OVX groups compared with the Control group, the amplitude of the cone-response was significantly lower in the OVX + STZ group than in the Control group (P = 0.013). At 12 weeks after STZ administration, this response showed a similar tendency in the STZ and the OVX + STZ groups. At 12 weeks after STZ administration, the implicit times of OP3 and OP4 and of the cone-response were significantly delayed in the STZ and OVX + STZ groups (OP3: P = 0.030 and 0.050, OP4: P = 0.0060 and 0.0053, cone-response: P = 0.014 and 0.039), compared with in the Control group. Thus, the retinal functions in STZ-induced diabetic female rats were aggravated by OVX. OVX-induced estrogen deficiency resulted in earlier changes in the amplitudes of cone-response, especially in the diabetes, although this is a transient effect and it is difficult to explain. Recognizing the early neurosensory change would enable a better understanding of the effect of estrogen in the retina. (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20153747     DOI: 10.1016/j.exer.2010.02.003

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  7 in total

1.  Menopause exacerbates visual dysfunction in experimental glaucoma.

Authors:  Andrew J Feola; Jieming Fu; Rachael Allen; Victoria Yang; Ian C Campbell; Amy Ottensmeyer; C Ross Ethier; Machelle Pardue
Journal:  Exp Eye Res       Date:  2019-06-18       Impact factor: 3.467

2.  Differential distribution of steroid hormone signaling networks in the human choroid-retinal pigment epithelial complex.

Authors:  Sydney M Galindez; Andrew Keightley; Peter Koulen
Journal:  BMC Ophthalmol       Date:  2022-10-20       Impact factor: 2.086

Review 3.  Is Estrogen a Therapeutic Target for Glaucoma?

Authors:  Samantha S Dewundara; Janey L Wiggs; David A Sullivan; Louis R Pasquale
Journal:  Semin Ophthalmol       Date:  2016       Impact factor: 1.975

4.  17β-estradiol eye drops protect the retinal ganglion cell layer and preserve visual function in an in vivo model of glaucoma.

Authors:  Katalin Prokai-Tatrai; Hua Xin; Vien Nguyen; Szabolcs Szarka; Balazs Blazics; Laszlo Prokai; Peter Koulen
Journal:  Mol Pharm       Date:  2013-07-23       Impact factor: 4.939

5.  Differences in Retinal Structure and Function between Aging Male and Female Sprague-Dawley Rats are Strongly Influenced by the Estrus Cycle.

Authors:  Samaneh Chaychi; Anna Polosa; Pierre Lachapelle
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

6.  Topical Estrogen Therapy for Hyperopia Correction in Vivo.

Authors:  Ari Leshno; Katalin Prokai-Tatrai; Ygal Rotenstreich; Asaf Magid; Ettel Bubis; Shulamit Schwartz; Alon Skaat; Ofira Zloto; Noa Avni-Zauberman; Adiel Barak
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-06-03       Impact factor: 4.799

Review 7.  Progression Rate of Visual Function and Affecting Factors at Different Stages of Retinitis Pigmentosa.

Authors:  Nana Ito; Gen Miura; Yuki Shiko; Yohei Kawasaki; Takayuki Baba; Shuichi Yamamoto
Journal:  Biomed Res Int       Date:  2022-07-14       Impact factor: 3.246

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.